Program
Inosine Monophosphate
Also written as “H5 Flu Investigational Medical Product (IMP) 1”, “GRT7040” and “IMP”.
Its studies are mostly in Osteoarthritis · Respiratory Syncytial Virus Infections · Acute Pain · Surgical Wound Infection, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 3since Nov 11, 2015 | Nov 11, 2015 | none ahead |
| Grünenthal | 11 open or running | phase 2since Sep 2, 2026 | Sep 2, 2026 | Sep 2027phase 2 · NCT07807644 |
| MB PHARMA s.r.o. | 11 open or running | phase 2since Mar 13, 2024 | Mar 13, 2024 | none ahead |
| Sanofi | 11 open or running | phase 1since Mar 31, 2026 | Mar 31, 2026 | Apr 4, 2027phase 1 · NCT07516418 |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 11, 2015First study: phase 3 study in OsteoarthritisNew to PfizerPfizer · NCT02674386 · 154 enrolled · United States, Australia, Canada and more
- Jan 17, 2017Phase 3 study in OsteoarthritisPfizer · NCT03031938 · 4 enrolled · United States
- Mar 13, 2024MB PHARMA s.r.o.’s first study: phase 2 study in Surgical Wound InfectionNew to MB PHARMA s.r.o.MB PHARMA s.r.o. · NCT06319235 · 52 planned · Czechia
- Mar 31, 2026Sanofi’s first study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to SanofiSanofi · NCT07516418 · 360 enrolled · Australia
- Sep 2, 2026Grünenthal’s first study: phase 2 study in Acute PainNew to GrünenthalGrünenthal · NCT07807644 · 400 planned
Ahead
- Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsSanofi · NCT07516418
- Sep 2027Primary completion: phase 2 study in Acute PainGrünenthal · NCT07807644
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07807644Acute Pain | 2 | Not yet recruiting | Grünenthal | Sep 2027 | 400 |
| NCT07516418Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Sanofi | Apr 4, 2027 | 360 |
| NCT06319235Surgical Wound Infection · Czechia | 2 | Recruiting | MB PHARMA s.r.o. | Dec 31, 2025 | 52 |
| NCT03031938Osteoarthritis · United States | 3 | Completed | Pfizer | Jun 4, 2020 | 4 |
| NCT02674386Osteoarthritis · United States, Australia, Canada and more | 3 | Completed | Pfizer | Jul 15, 2019 | 154 |
How it is read
Names in the registry
- “H5 Flu Investigational Medical Product (IMP) 1”, 1 entry
- “GRT7040”, 1 entry
- “IMP”, 1 entry
- “Investigational medical product (IMP) administered in parent study”, 1 entry
- “Investigational Medical Product (IMP) administered in parent study”, 1 entry
Conditions, from the studies’ own filings
- Osteoarthritis, 2 studies
- Respiratory Syncytial Virus Infections, 1 study
- Acute Pain, 1 study
- Surgical Wound Infection, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.